Code : 9345-345038      Created Date : Monday, February 16, 2015   Update Date : Monday, February 16, 2015    Visit : 1966

Pharmacology 2013 Winter meeting of Britiah Pharmacological Society

The report of Pharmacology 2013 - Winter meeting of British Pharmacological Society by Dr. Shahin Akhondzadeh
 
Application Code :
306-0114-0002
 
Created Date : Saturday, January 11, 2014 22:32:52Update Date : Monday, January 27, 2014 22:55:15IP Address :151.241.195.219
Submit Date : Monday, January 27, 2014 22:55:30Email : s.akhond@neda.net
Personal Information
Name : Shahin
Surname : Akhondzadeh
School/Research center : School of Medicine
If you choose other, please name your Research center :  
Possition : Professor
Tel : +98-21-66418466
Information of Congress
Title of the Congress : Pharmacology 2013
Winter meeting of Britiah Pharmacological Society
Title of your Abstract : Comparing efficacy and safty of crocus sativus L. with memantine in patients with moderate to severe Alzhiemer's Disease: A double blind randomised clinical trial
country : England
From : Tuesday, December 17, 2013
To : Thursday, December 19, 2013
Abstract(Please copy/paste the abstract send to the congress) : Alzheimer’s disease (AD), the leading cause of dementia worldwide, is an irreversible progressive neurodegenerative disorder characterized by cognitive impairment, and functional disability. Management of the severe stages of Alzheimer’s disease (AD) is a great challenge and limited pharmacological options are currently available. The dried stigma of Crocus sativus L., called saffron, can target some pathologic processes of AD and its cognitive-enhancing properties have been evidenced in different studies. We previously investigated the efficacy and safety of saffron for mild to moderate AD in two separate clinical trials (1, 2). Interestingly, saffron constituents have been shown to decrease extracellular glutamate levels and exert antagonist effects on NMDA receptors; a function which can be compared to memantine’s mechanism of action. We aimed to compare the efficacy and safety of saffron versus memantine in reducing cognitive deterioration of patients with moderate to severe AD.
In this randomized double-blind parallel-group study, 68 patients with moderate to severe AD (Mini Mental State Examination score: 8-14) were randomized to receive memantine (20 mg/day) or saffron (30 mg/day) for twelve months. Participants were evaluated monthly by the Severe Cognitive Impairment Rating Scale (SCIRS) and Functional Assessment Staging (FAST) in addition to recording probable adverse events. The trial protocol was approved by the institutional review board (IRB) of Tehran University of Medical Sciences and performed in accordance with the Declaration of Helsinki and its subsequent revisions. General linear model repeated measures analysis was used in order to assess effect of time × treatment interaction, considering the treatment group (saffron vs. memantine) as the between-subject factor and the study measurements as the within-subject variables (time).
One hundred and fourteen individuals were screened for the eligibility criteria and sixty-eight patients were randomized into two groups. One patient in each group died during this trial due to reasons not related to the study and a total number of sixty patients (saffron=30, memantine=30) completed the trial. Both treatment groups showed similar behaviour during this trial as demonstrated by insignificant effects for time × treatment interaction on SCIRS scores as our primary outcome measure [F(2.95, 194.78)=2.25, P=0.08]. There was no significant difference between the two groups in score changes from baseline to the endpoint on SCIRS (P=0.38) and FAST (P=0.87). Patient vital signs, laboratory tests, and ECG did not change significantly from baseline to the final visit. Based on the adverse events checklist, a total number of seven side effects were reported during this trial which were all mild and resolved spontaneously without any intervention. No significant difference was detected between two groups in the frequency of the adverse events.
In addition to its favourable safety profile, one year administration of saffron capsules showed to be as effective as memantine in reducing cognitive decline in patients with moderate to severe AD. Confirmatory studies with larger sample sizes and longer follow-up periods are warranted.

(1) Akhondzadeh S, Sabet MS, Harirchian MH et al. (2010) J Clin Pharm Tehr 25: 581-588.
(2) Akhondzadeh S, Shafiee Sabet M, Harirchian MH et al (2010) Psychopharmacology 207: 637-43.
Keywords of your Abstract : Saffron, Memantine, Alzheimer's Disease
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/15395/Forms/306/Shahin Akhondzadeh-BPS Acceptance_1.pdf
The presentation : Oral
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/15395/Forms/306/Cover of BPS abstract book0001_1.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/15395/Forms/306/BPS-Abstract0001_1.pdf
Where has your abstract been indexed? : other
If you choose other, please name : PA2 online
The Congress Reporting Form
How many volunteers were present at the Congress? : more than 1000
Delegates from which countries presented in the congress? : more than 30 contries: Germany, Australia, China, Suadi Arabia, France....
Were the delegates of any other organizations present in the congress? : No
If yes, please write the names of the organizations in the box :  
What were the responses to your talking points? Were specific questions or concerns raised? : It was interesting for audience and asked a number of good quistions regarding the follow up of the study and future studies with Crocus sativus in the treatment of AD
If you met staff members, please list their full names & positions. : a number including Pro. TW Stone
Please inform us if there are any follow up actions we need to talk with the members of the congress : It was interesting for audience and asked a number of good quistions regarding the follow up of the study and future studies with Crocus sativus in the treatment of Alzheimer,s disease and inparticular with comparisin with other medication such as donepezil, rivastigmine and galantamine and also in the reatment of other stage of Alzheimer,s disease
Your experiences about the travel processes(Providing ticket, accommodation,...) : not bad
Please give a briefing of your own observations and outcomes of the congress: : The BPS meeting is very famous in the world. Engaging with the policy landscape is an essential part of BPS fulfilling its strategic objectives. The active input of our members during, and on, the process is appreciated. A policy processes document has been developed to support their involvement. My presentation was was interesting for audience and asked a number of good quistions regarding the follow up of the study and future studies with Crocus sativus in the treatment of Alzheimer,s disease and inparticular with comparisin with other medication such as donepezil, rivastigmine and galantamine and also in the reatment of other stage of Alzheimer,s disease

 

Your Comments :
captcha
Close